Five research organisations from the EU and South Korea signed today a letter of intent (LOI) for international joint research on COVID-19 treatment. This agreement covers the exchange of clinical and nonclinical trial information related to their research on COVID-19 treatment using the repurposed Raloxifene molecule.

Three Korean (Gyeonggido Business and Science Accelerator (GBSA), the National Korean Institute of Health (NIH), and the Korea Institute of Science and Technology Information (KISTI)) and two EU-funded research organisations (Dompe Farmaceutici and the national Italian supercomputing centre CINECA) have agreed to undertake joint research with the goal of accelerating the development of a COVID-19 treatment. This follows independent research carried out on both sides, including the use of supercomputers, which have concluded that Raloxifene is effective in COVID-19 treatment within the Exscalate4CoV project. Currently, clinical trials are taking place in Italy, in order to validate the safety and efficiency of Raloxifene in blocking the replication of the virus in cells and therefore holding up the progression of the disease.

Under the agreement, the participating organizations (Gyeonggido Business and Science Accelerator, Dompè and CINECA)  on both sides facilitate the exchange of information pertaining to non-clinical and clinical trial plans as well as characteristics of raloxifene and COVID-19 antiviral materials revealed through supercomputer analysis. 

More information in the press release